Introduction
First recognized by Cowper et al. in 1997 [1] , nephrogenic fibrosing dermopathy (NFD) was initially identified in 15 renal dialysis patients who developed thickening and hardening of the skin with brawny hyperpigmentation, papules and subcutaneous nodules of the extremities. The process resembled scleromyxedema but clinical and histopathological features warranted the designation of a new distinct clinicopathological entity. Since its first published description in 2000, NFD has been seen exclusively in patients with renal disease and mostly affects the skin and subcutaneous tissue. Recent reports describing involvement of additional organs, and the observation that the disease is mediated by a circulating cell, imply that NFD is a systemic disease [2, 3, 4 ] . Accordingly, a change to the more descriptive name, nephrogenic systemic fibrosis (NSF), was considered to more accurately reflect disease nosology [5 ] . Other eponyms such as scleromyxedema-like illness of renal disease, scleromyxedema-like illness of hemodialysis, scleromyxedema-like fibromucinosis, dialysis-associated systemic fibrosis may also be found in the literature in association with this entity [1, 3, 6, 7] . To date the NSF Registry at Yale University has established 200 cases [5 ] . The United States Center for Disease Control and Prevention has been alerted to this entity since 2002, but no comprehensive, epidemiologic studies have been performed yet [8] . The cause of NSF is unknown and its pathogenesis remains unclear.
Epidemiology NSF occurs equally in both sexes, ranging in age from 8 to 87 years old (mean 46.4 years old). There is no race predilection [5 ,9] . Cases have been reported in the US, and several countries in Europe and Asia, but none to date in Canada or Australia.
Clinical presentation
Thus far, all documented cases of NSF have occurred in patients with renal disease, most of which are dialysis dependent. Clinically, cutaneous changes are most apparent and present as symmetric coalescing skin hardening, often with a peau d'orange appearance or textured plaques, papules or nodules. The edge of lesions may have a distinctive irregular border, resembling amoeboid projections. Erythematous or brown pigmentary changes may or may not be present. The extremities are most commonly involved with a distribution from ankles to mid-thighs and from wrists to mid-upper arms (see Fig. 1 ). Less often involvement of the trunk has been reported. Swelling of the hands and feet with occasional bullae may also be rarely seen. Given the acute presentation, NSF is frequently misdiagnosed and treated as edema or cellulitis, the resolution of which leaves the involved areas markedly thickened with a woody texture. The involved joints may develop contractures with a decrease in function, often leading to the patent's debilitation within a few weeks, or even days. Affected areas may be accompanied by pruritus and sharp pain [1,5 ,6,9,10] Yellow asymptomatic scleral plaques similar to pinguicula have been found in some patients. The histopathologic findings in these plaques have not been described yet [11] . Involvement of skeletal muscle and fascia can also be seen [12] . Calciphylaxis has been reported in association with NFD/NSF [13] . A subset of patients have involvement of multiple organ systems, including heart, lungs, skeletal muscles and diaphragm, which can eventually cause death. Extensive fibrosis of renal tubules and rete testes has also been noted [2, 3, 4 ] .
Associated co-morbidities
In addition to renal disease, a multitude of other comorbidities have been reported with NSF, including hypercoagulability and thrombotic events, cardiomyopathy, hepatic disease, idiopathic pulmonary fibrosis, systemic lupus erythematosus and brain tumors [5 ,9,10,14] . Reported causes of renal diseases in patients with NSF are widely variable. The severity of symptoms of NSF does not seem to be related to the cause or degree of the underlying renal dysfunction. Lastly, surgical procedures, in particular those with a vascular reconstructive component, have been associated with the onset of NSF in some individuals.
Etiology and pathogenesis
To date there is no known cause for this disease. The fact that the first described cases of NSF occurred in 1997 is curious and intriguing. A few questions become essential. Did NSF exist before then? The most likely histologic mimic of NSF is scleromyxedema. In an attempt to answer this question, two large tissue repositories were searched for cases of NSF prior to 1997, using search terms for scleromyxedema. No cases were found in either of these centers. In addition, long-time practitioners of dermatology at several centers have indicated that they do not recall having seen NSF before 1997. By these measures, it would appear NSF is indeed a new condition.
A case matched study undertaken by the Centers for Disease Control failed to isolate a single mediator (drug, medical technique, chemical or infectious agent) that could explain every case of NSF. The single relating factor in all patients is the underlying kidney disease. Most of the patients are dialysis-dependent; there is no supporting evidence, however, that dialysis induces NSF, since some patients have never been dialyzed [1,5 ,9,10] . The end product of the process is fibrosis that resembles the proliferative stages of wound healing. A postulated theory involves the circulating fibrocyte, which is a bone marrow-derived, connective tissue cell that is found in the peripheral circulation and mesenchymal tissue [15] . First described in 1994 in model systems of wound repair, these cells enter sites of inflammation and tissue repair and secrete growth factors and cytokines, contributing to connective tissue matrix production [16 ] . Fibrocytes have a specific immunophenotype and express CD34, CD11b, CD45, HLA-DR, CD71, CD80, CD86, which support their hematopoietic origin. Fibrocytes have been shown to be recruited in response to tissue injury, perhaps endothelial disruption, and they produce inflammatory cytokines, chemokines, growth and angiogenic factors. Fibrocytes are also a source of vimentin, collagen I and III, and matrix metalloproteinases [17] . Some reports show extensive hyaluronidase deposition in the papillary dermis in affected patients [18] . Under the influence of various mediators, such as transforming growth factor (TGF)-b, fibrocytes can differentiate into myofibroblasts. Myofibroblasts appear to represent a small proportion of the spindle cells in NSF. Increased levels of TGF-b have been found in the skin and muscle of some affected patients [3] and in association with drugs used in renal therapy [19, 20] .
Cutaneous biopsies obtained from NSF patients typically contain no mitotic figures, suggesting that the CD34 þ / collagen þ fibrocytes that are present arise by recruitment from the circulation and not by proliferation in situ. Further research is ongoing to elucidate the molecular signals that may control fibrocyte recruitment and trafficking into skin, which may be dysregulated in NSF. Attention to these signals may provide for potential therapeutic opportunities.
Diagnosis
NSF is a clinical and histopathologic diagnosis, and no single, unique test establishes the diagnosis. The clinical presentation described above, together with the medical history of kidney disease is very important. Laboratory studies support the findings of underlying renal insufficiency or accompanying co-morbidities. Unlike the findings in scleromyxedema, there is no evidence of monoclonal paraprotein in the serum [1,5 ,9,10] .
Histopathologic tissue examination is considered the gold standard in establishing the diagnosis of NSF. Lesions contain a proliferation of dermal spindle cells, which may extend into subcutaneous tissue; therefore a deep biopsy is essential. The spindle cells are bland and demonstrate long dendritic processes. A prominent finding is the thick collagen bundles with surrounding clefts and a variable amount of mucin and elastic fibers (Fig. 2) . The staining profile of these dendritic cells has been described above. Scattered (and sometimes prominent) epithelioid to stellate cells may stain for CD68 implying a histiocytic differentiation. These may contain multiple nuclei, and on rare occasions may resemble osteoclasts. Other prominent stellate cells are factor XIIIa positive, and seem to represent an overabundance of this usual resident cell of the papillary and periadnexal dermis. Inflammatory cells are not usually evident, although small clusters of perivascular mononuclear cells may be seen.
Limited observations have not revealed an association with Epstein-Barr virus or amyloid deposits. Occasional foci of mineralization are reported.
Electron microscopy studies of the skin show dendritic cells with prominent rough endoplasmic reticulum surrounded by elastic fibers and collagen bundles [21] .
Differential diagnosis
A list of differential diagnoses includes but is not limited to scleroderma, scleromyxedema, systemic sclerosis/ morphea, eosinophilic fasciitis, eosinophilia-myalgia syndrome, Spanish toxic oil syndrome, scleredema of Buschke, chemical induced fibrosis, fibroblastic rheumatism, amyloidosis, carcinoid syndrome, borreliosis, porphyria cutanea tarda, calcifilaxis, dermatofibrosarcoma protuberans. In early stages NSF may mimic cellulitis, panniculitis and drug reactions. Discussions of the clinical, laboratory and histopathological differential diagnoses have been previously published [6, [9] [10] [11] .
Treatment
Since the cause and pathogenesis are not fully understood yet, therapeutic measures with proven efficacy are deficient to date. There have been anecdotal reports of patients showing some response to thalidomide, and published reports (often of single cases) of improvements with extracorporeal photopheresis, plasmapheresis, ultraviolet phototherapy and intravenous immunoglobulin [22] [23] [24] [25] [26] . Several cases of reversal of the disease by renal replacement, have appeared in the literature (or are known to the authors) [27] .
616 Raynaud phenomenon, scleroderma, overlap syndromes and other fibrosing syndromes 
Conclusion
First recognized as a dermatological process in 1997, today there is enough supporting evidence that NSF is systemic in its nature. While we have acquired some understanding of the pathogenesis, with the fibrocyte being the main cellular suspect, the full disease mechanism is still evolving. Of great interest is the recent report of Grobner, suggesting a causal link with the magnetic resonance imaging contrast agent, gadolinium [28 ] . Until this report can be fully evaluated, however, recognizing, reporting and continuous surveillance of the affected patients and treatment advancement is essential. Research is underway regarding molecular signals that control fibrocyte migration, proliferation and function. Further studies are needed to focus on the precipitating exposures or immunological factors that are unique to these patients and to the NSF disease process.
Updates and information regarding case submission can be found at the official website of The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR) at: http://www.icnfdr.org directed by Shawn E. Cowper, MD.
